NATRIX-BNPNCT06237309
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 19, 2026; versions filed since then are not listed here yet.
All 20 versions: 20 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Results posted: Nov 19, 2026
- Stopped Trial status: Active, Not Recruiting to Terminated Sponsor's reason: Sponsor decision
- Study completion date changed from estimate of Dec 30, 2025 to Dec 29, 2025
Minor Trial status: Recruiting to Active, Not Recruitingv19 Show 4 more changesShow less
- Enrollment target: estimated 394 to confirmed 89
- Primary completion date changed from estimate of Nov 6, 2026 to Sep 17, 2025
- Study completion date: Feb 17, 2027 to Dec 30, 2025
- Site details revised at 44 of 44 sites
Notable Primary completion date: Jan 2, 2026 to Nov 6, 2026v18 Show 7 more changesShow less
- Eligibility criteria expanded, about 13 words
- Enrollment target: 391 to 394
- Study sites: 42 to 44
- Study completion date: Apr 15, 2026 to Feb 17, 2027
- Secondary endpoints revised (13)
- Primary endpoint revised
- Study description expanded, about 11 words
- Minor Study sites: 39 to 42v17
Show 15 earlier versionsHide 15 earlier versions
- Minor Study sites: 33 to 39v16
- Minor Study sites: 24 to 33v15
- Minor Study sites: 15 to 24v14
- Minor Study sites: 14 to 15v13
- Notable Eligibility criteria expanded, about 14 words
- Study arms: 10 to 12
- Minor Study sites revised (14)v11
- Notable Eligibility criteria shortened, about 14 words
- Study title shortened, about 11 words
- Minor Study sites: 13 to 14v9
- Minor Study sites: 12 to 13v8
- Minor Study sites: 9 to 12v7
- Minor Study sites: 7 to 9v6
- Minor Study sites: 6 to 7v5
- Minor Study sites: 1 to 6v4
- Notable Eligibility criteria expanded, about 25 words
- Primary completion date: Apr 10, 2026 to Jan 2, 2026
- Study completion date: Jul 22, 2026 to Apr 15, 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of May 2, 2024 to Apr 11, 2024
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Single ascending dose cohort
Single ascending dose cohort
Single ascending dose cohort
Single ascending dose cohort
Single ascending dose cohort
Single ascending dose cohort. Note: This group has been closed
Single ascending dose cohort. Note: This group has been closed
Note: This group has been closed
Drugs: REGN5381, Placebo
Sites
44 sites in 12 countries
Belgium 8, Poland 5, Czechia 4, Greece 4, South Africa 4, South Korea 4, Spain 4, United States 4, Bulgaria 3, Romania 2, Georgia 1, Moldova 1